LHCGR and cancer: The cytotoxicity of the lytic peptide Phor21 or its shorter version Phor14 has been successfully tested in combination with βCG (Phor21-βCG) to target LHCGR-positive breast (Hansel et al. 2007a, b), prostate (Leuschner et al. 2003) and ovarian (Gawronska et al. 2002) cancer cells in vitro and in xenografts.